Reflections of a Medical Oncologist on AACR 2013

Guest post on AACR 2013 by Philippe Aftimos, MD a medical oncologist at Institut Jules Bordet in Brussels with his reflections on new developments in cancer biomarkers and clinical trial design.

April 22, 2013

Overcoming drug resistance in lung cancer

Update on new techniques for identifying and overcoming resistance in advanced lung cancer

April 17, 2013

Overcoming resistance to vemurafenib in metastatic melanoma

Meghna Das Thakur from Novartis shows that treating with BRAF inhibitor with intermittent dosing lead to improved survival for metastatic melanoma

April 15, 2013

AACR 2013 – some initial thoughts on the emerging trends

There were around 6,000 posters and many oral sessions at this year's AACR meeting in Washington DC, but what new trends emerged this year?

April 11, 2013

Bromodomain Inhibitors – an exciting new target in cancer research?

Bromodomain inhibition is a novel cancer target and one that I am looking forward to learning more about at forthcoming annual meeting of the American Association for Cancer Research (AACR) in Washington DC.

March 11, 2013